AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02288923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sub arachnoid analgesia
Description: Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
Study NCT00551213 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Robatumumab
Study NCT00551213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Study NCT00551213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT01786265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given via injection
Study NCT01786265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given via injection
Study NCT01786265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given via injection
Study NCT00551213 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Study NCT00551213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT00551213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
Study NCT00551213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX/XELOX
Description: Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
Study NCT01786265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given via injection
Study NCT01786265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilutamide
Description: Given PO
Study NCT00551213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
Study NCT01144117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoietin 48000 IU given I.V. in 17 courses
Study NCT02288923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation or general anaesthesia
Description: After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
Study NCT02288923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-medication
Description: All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
Study NCT02107274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
Study NCT02107274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Azithromycin
Description: In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
Study NCT02578602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetate Disodium
Description: Given IV
Study NCT02578602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI with gadoxetate disodium
Study NCT02293707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX301
Description: GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG.
Study NCT01786265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilutamide
Description: Given PO
Study NCT01786265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT01946854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year.
Study NCT01946854 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year.
Study NCT02781519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Active THC (0.015mg/kg) administered over 10 minutes
Study NCT02781519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
Study NCT06094738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant under fasted conditions
Description: Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
Study NCT02789878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Androgen Deprivation Therapy
Study NCT02288923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative medication
Description: If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
Study NCT02288923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative analgesia - morphine
Description: Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight >70kg 2 hourly.
Study NCT01084161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 5 mg IV once per day
Study NCT01084161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 7.5 mg IV once per day
Study NCT01084161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 15 mg IV once per day
Study NCT01084161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 30 mg IV once per day
Study NCT01084161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV placebo once per day
Study NCT02288923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative analgesia - ibuprofen and paracetamol
Description: All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
Study NCT02288923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular anti emetics
Description: All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
Study NCT01084161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 10-15 mg IV once per day
Study NCT01084161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 60 mg IV once per day
Study NCT01260974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: 50mg/dd for 21dd, starting within 24h from Liver Transplantation.
Study NCT03940469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml normal saline
Study NCT03940469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Injection
Description: 8 mg dexamethasone
Study NCT03940469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: 100 microgram dexmedetomidine
Study NCT02477943 — intervention group
Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
Study NCT01067794 — intervention group
Intervention type: DRUG
Intervention: Any platinum-based doublet chemotherapy
Description: Dosage, dosage form, frequency and duration according to daily hospital practice
Study NCT05694117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-determine sequence exercise program
Description: The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
Study NCT06094738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant after a high-fat meal
Description: Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal
Study NCT06094738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant after a low-fat meal
Description: Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
Study NCT04555239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model (FDM)
Description: Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~* Herniated trigger points are single areas of sharp pain within soft tissue.~* Continuum distortions are single points of sharp pain overlying bony tissues.~* Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands.
Study NCT02789878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Corticosteroid
Study NCT04555239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: The usual standard of care for extremity pain varies from provider to provider and varies from patient to patient depending upon their comorbidities but often includes some combination of the following:~* X-rays, if suspicion for fracture exists~* Venous duplex ultrasound, if suspicion for DVT/SVT exists~* Computed tomography (CT) angiogram (CTA), if suspicion for arterial occlusion exists~* C-reactive Protein (CRP)/erythrocyte sedimentation rate (ESR)/arthrocentesis is suspicion if suspicion for septic arthritis exists~* Arthrocentesis if suspicion for gout exists~* Splinting/casting/immobilization~* NSAIDs, Tylenol, or opioids for pain control~* Possibly trigger point injections~* Possibly osteopathic manipulation~* Recommendations to use RICE (rest, ice, compression, elevation) at home~* Physical/occupational therapy referral~* Orthopedic referral
Study NCT04555239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The usual standard of care for extremity pain varies from provider to provider and varies from patient to patient depending upon their comorbidities but often includes some combination of the following:~* X-rays, if suspicion for fracture exists~* Venous duplex ultrasound, if suspicion for DVT/SVT exists~* Computed tomography (CT) angiogram (CTA), if suspicion for arterial occlusion exists~* C-reactive Protein (CRP)/erythrocyte sedimentation rate (ESR)/arthrocentesis is suspicion if suspicion for septic arthritis exists~* Arthrocentesis if suspicion for gout exists~* Splinting/casting/immobilization~* NSAIDs, Tylenol, or opioids for pain control~* Possibly trigger point injections~* Possibly osteopathic manipulation~* Recommendations to use RICE (rest, ice, compression, elevation) at home~* Physical/occupational therapy referral~* Orthopedic referral
Study NCT02789878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: CYP17 inhibitor
Study NCT02789878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Androgen-receptor antagonist
Study NCT04559334 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tetrasodium EDTA Catheter Lock Solution
Description: KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
Study NCT04000880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health
Description: AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
Study NCT04000880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet-Exercise
Description: Diet-Exercise
Study NCT04000880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-Diet
Description: Exercise-Diet
Study NCT04000880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Diet and Exercise
Description: Combined Diet and Exercise
Study NCT05694117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.
Study NCT05694117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taichi exercise and resistance training
Description: The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
Study NCT05694117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Randomly selected exercise program
Description: Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
Study NCT03564873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
Study NCT03564873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
Study NCT03564873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
Study NCT04038645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental group (laser)
Description: The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol.
Study NCT04038645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Placebo)
Description: Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.